+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Polyclonal Antibodies Market Size, Share & Trends Analysis Report By Product (Primary, Secondary), By Application (Biomedical Research, Diagnostics), By Source (Rabbit, Goats), By End-user, By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 110 Pages
  • May 2023
  • Region: Global
  • Grand View Research
  • ID: 5830905
Description Jump to:
The global polyclonal antibodies market size is anticipated to reach USD 2.21 billion by 2030. The market is expected to expand at a CAGR of 5.01% from 2023 to 2030. The increasing technological advancements in the production of antibodies-based drugs, the growing prevalence of infectious & chronic diseases such as cancer across the globe, and the rising number of biopharmaceutical research and development activities are the main drivers of the industry. In addition, Polyclonal antibodies (pAbs) are extensively utilized in both quantitative and qualitative biological research as well as several diagnostic tests.

The use of polyclonal antibodies has had a positive impact on the treatment of COVID-19 patients, with studies showing that these therapies can reduce hospitalization rates and improve outcomes for patients with mild to moderate disease. Additionally, the development of pAbs has helped to advance the understanding of the immune response to COVID-19 and is projected to lead the development of more effective treatments and vaccines in the future. Thus, the COVID-19 pandemic has had a significant impact on the pAbs market.

Several government initiatives support and promote the development and use of polyclonal antibodies in various applications, including diagnostics, therapeutics, and research. These initiatives are aimed at improving healthcare outcomes, promoting innovation, and supporting the growth of the biotechnology and pharmaceutical industries. Moreover, many governments are also taking initiatives to promote collaborations between academic institutions, research organizations, and industry players in the pAbs market. For instance, in May 2020, the Canadian Government invested USD 175 million in AbCellera, to support the organization in its antibody treatment examination and the production of the antibody construction facility. Thus, such various government initiatives are anticipated to increase the demand for the pAbs market.

Polyclonal Antibodies Market Report Highlights

  • Based on the product, the secondary antibodies segment dominated in terms of the revenue share of 56.14% in 2022, owing to the high sensitivity and enhanced signal amplification quality, thus increasing the demand in the industry
  • Based on end-user, the hospital & diagnostic centers segment dominates in terms of the revenue share of 59.81% in 2022. This is attributed to the increasing demand for pAbs-based assays in diagnostic centers and the rising prevalence of chronic & infectious diseases
  • Based on application, the diagnostics segment dominated in terms of the revenue share of 59.81% in 2022. Due to the ability of pAbs to recognize the epitopes of targeted molecules, it is regarded as the optimum reagent in hemagglutination assays and diagnostics. Thus, increasing the demand for diagnostics in the application segment
  • Based on source, the rabbit segment dominated in terms of the revenue share of 50.69% in 2022. Abs from rabbits have a high level of specificity and can bind to a variety of proteins at picomolar concentrations. Hence, the demand for rabbit-based Abs is expected to increase in the future
  • In 2022, North America dominated with a revenue share of over 38.62%, due to various factors, such as advancements in technology and healthcare infrastructure. The presence of a large number of biotechnology and pharmaceutical industry players is anticipated to increase the overall research and development of various antibody-based drugs, resulting in market growth
  • Asia Pacific accounted for the fastest-growing region with a CAGR of 9.67% during the forecast period. The increasing prevalence of chronic diseases and rising demand for personalized medicine are expected to fuel the upsurge in the market


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Definitions
1.1.1.1 Product Segment
1.1.1.2 Application Segment
1.1.1.3 Source Segment
1.1.1.4 End-Use Segment
1.2 Information Procurement
1.2.1 Market Formulation & Data Visualization
1.2.2 Data Validation & Publishing
1.3 Research Assumptions
1.4 Research Methodology
1.4.1 Purchased Database
1.4.2 Gvr’s Internal Database
1.4.3 Secondary Sources
1.4.5 Primary Research
1.4.6 Details Of Primary Research
1.5 Information or Data Analysis
1.5.1 Data Analysis Models
1.6 Market Formulation & Validation
1.7 Model Details
1.7.1 Commodity Flow Analysis
1.7.1.1 Approach 1: Commodity Flow Approach
1.8 List Of Secondary Sources
1.9 Global Market: Cagr Calculation
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot 1
2.3 Segment Snapshot 2
2.4 Competitive Landscape Snapshot
Chapter 3 Polyclonal Antibodies Market Variables and Trends
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Market Dynamics
3.2.1 Market Driver Impact Analysis
3.2.1.1 Increasing Prevalence Of Chronic And Infectious Diseases
3.2.1.2 Increasing Biopharmaceutical R&D Activities
3.2.1.3 Growing Demand For Personalized Medicines
3.2.1.4 Increasing Technological Advancements
3.2.2 Market Restraint Impact Analysis
3.2.2.1 Stringent regulations and ethical concerns regarding polyclonal antibody production
3.3 Impact of COVID-19 Pandemic
3.4 Industry Analysis Tools
3.4.1 Porter’s Analysis
3.4.2 Swot Analysis, By Factor (Political & Legal, Economic, And Technological)
Chapter 4 Polyclonal Antibodies Market: Product Estimates & Trend Analysis
4.1 Product Movement Analysis & Market Share, 2022 & 2030
4.2 Polyclonal Antibodies Market Estimates & Forecast, By Product (USD Million)
4.3 Primary Antibodies
4.3.1 Global Primary Antibodies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4 Secondary Antibodies
4.4.1 Global Secondary Antibodies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 5 Polyclonal Antibodies Market: Application Estimates & Trend Analysis
5.1 Application Movement Analysis & Market Share, 2022 & 2030
5.2 Polyclonal Antibodies Market Estimates & Forecast, By Application (USD Million)
5.3 Biomedical Research
5.3.1 Global Biomedical Research Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.4 Diagnostics
5.4.1 Global Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 6 Polyclonal Antibodies Market: Source Estimates & Trend Analysis
6.1 Source Movement Analysis & Market Share, 2022 & 2030
6.2 Polyclonal Antibodies Market Estimates & Forecast, By Source (USD Million)
6.3 Rabbits
6.3.1 Global Rabbits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4 Goats
6.4.1 Global Goats Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.5 Sheep
6.5.1 Global Sheep Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.6 Mouse
6.6.1 Global Mouse Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.7 Others
6.7.1 Global Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 7 Polyclonal Antibodies Market: End-User Estimates & Trend Analysis
7.1 End-User Movement Analysis & Market Share, 2022 & 2030
7.2 Polyclonal Antibodies Market Estimates & Forecast, By End-User (USD Million)
7.3 Pharmaceutical & Biotechnology Companies
7.3.1 Global Pharmaceutical & Biotechnology Companies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4 Hospitals & Diagnostic Centers
7.4.1 Global Hospitals & Diagnostic Centers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5 Academic & Research Center
7.5.1 Global Academic And Research Center Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 8 Polyclonal Antibodies Market: Regional Estimates and Trend Analysis
8.1 Polyclonal Antibodies Market: Regional Outlook
8.2 North America
8.2.1 North America Polyclonal Antibodies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.2.2 U.S.
8.2.2.1 Key Country Dynamics
8.2.2.2 Competitive Scenario
8.2.2.3 Regulatory Landscape
8.2.2.4 U.S. Polyclonal Antibodies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.2.3 Canada
8.2.3.1 Key Country Dynamics
8.2.3.2 Competitive Scenario
8.2.3.3 Regulatory Landscape
8.2.3.4 Canada Polyclonal Antibodies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.3 Europe
8.3.1 Europe Polyclonal Antibodies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.3.2 UK
8.3.2.1 Key country dynamics
8.3.2.2 Competitive scenario
8.3.2.3 Regulatory Landscape
8.3.2.4 UK polyclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
8.3.3 Germany
8.3.3.1 Key country dynamics
8.3.3.2 Competitive scenario
8.3.3.3 Regulatory Landscape
8.3.3.4 Germany polyclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
8.3.4 France
8.3.4.1 Key country dynamics
8.3.4.2 Competitive scenario
8.3.4.3 Regulatory Landscape
8.3.4.4 France polyclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
8.3.5 Italy
8.3.5.1 Key country dynamics
8.3.5.2 Competitive scenario
8.3.5.3 Regulatory Landscape
8.3.5.4 Italy polyclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
8.3.6 Spain
8.3.6.1 Key country dynamics
8.3.6.2 Competitive scenario
8.3.6.3 Regulatory Landscape
8.3.6.4 Spain polyclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
8.3.7 Denmark
8.3.7.1 Key country dynamics
8.3.7.2 Competitive scenario
8.3.7.3 Regulatory Landscape
8.3.7.4 Denmark polyclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
8.3.8 Sweden
8.3.8.1 Key country dynamics
8.3.8.2 Competitive scenario
8.3.8.3 Regulatory Landscape
8.3.8.4 Sweden polyclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
8.3.9 Norway
8.3.9.1 Key country dynamics
8.3.9.2 Competitive scenario
8.3.9.3 Regulatory Landscape
8.3.9.4 Norway polyclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
8.4 Asia Pacific
8.4.1 Asia Pacific Polyclonal Antibodies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.2 China
8.4.2.1 Key country dynamics
8.4.2.2 Competitive scenario
8.4.2.3 Regulatory Landscape
8.4.2.4 China polyclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
8.4.3 Japan
8.4.3.1 Key country dynamics
8.4.3.2 Competitive scenario
8.4.3.3 Regulatory Landscape
8.4.3.4 Japan polyclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
8.4.4 India
8.4.4.1 Key country dynamics
8.4.4.2 Competitive scenario
8.4.4.3 Regulatory Landscape
8.4.4.4 India polyclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
8.4.5 South Korea
8.4.5.1 Key country dynamics
8.4.5.2 Competitive scenario
8.4.5.3 Regulatory Landscape
8.4.5.4 South Korea polyclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
8.4.6 Australia
8.4.6.1 Key country dynamics
8.4.6.2 Competitive scenario
8.4.6.3 Regulatory Landscape
8.4.6.4 Australia polyclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
8.4.7 Thailand
8.4.7.1 Key country dynamics
8.4.7.2 Competitive scenario
8.4.7.3 Regulatory Landscape
8.4.7.4 Thailand polyclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
8.5 Latin America
8.5.1 Latin America Polyclonal Antibodies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.2 Brazil
8.5.2.1 Key country dynamics
8.5.2.2 Competitive scenario
8.5.2.3 Regulatory Landscape
8.5.2.4 Brazil polyclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
8.5.3 Mexico
8.5.3.1 Key country dynamics
8.5.3.2 Competitive scenario
8.5.3.3 Regulatory Landscape
8.5.3.4 Mexico polyclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
8.5.4 Argentina
8.5.4.1 Key country dynamics
8.5.4.2 Competitive scenario
8.5.4.3 Regulatory Landscape
8.5.4.4 Argentina polyclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
8.6 MEA
8.6.1 MEA Polyclonal Antibodies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.2 South Africa
8.6.2.1 Key country dynamics
8.6.2.2 Competitive scenario
8.6.2.3 Regulatory Landscape
8.6.2.4 South Africa polyclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
8.6.3 Saudi Arabia
8.6.3.1 Key country dynamics
8.6.3.2 Competitive scenario
8.6.3.3 Regulatory Landscape
8.6.3.4 Saudi Arabia polyclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
8.6.4 UAE
8.6.4.1 Key country dynamics
8.6.4.2 Competitive scenario
8.6.4.3 Regulatory Landscape
8.6.4.4 UAE polyclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
8.6.5 Kuwait
8.6.5.1 Key country dynamics
8.6.5.2 Competitive scenario
8.6.5.3 Regulatory Landscape
8.6.5.4 Kuwait polyclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 9 Polyclonal Antibodies Market: Competitive Landscape
9.1 Participant Categorization
9.1.1 THERMO FISHER SCIENTIFIC INC.
9.1.1.1 Overview
9.1.1.2 Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.1.3 Product Benchmarking
9.1.1.4 Strategic Initiatives
9.1.2 MERCK KGAA
9.1.2.1 Overview
9.1.2.2 Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.2.3 Product Benchmarking
9.1.2.4 Strategic Initiatives
9.1.3 ABCAM PLC.
9.1.3.1 Overview
9.1.3.2 Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.3.3 Product Benchmarking
9.1.3.4 Strategic Initiatives
9.1.4. PROTEOGENIX
9.1.4.1 Overview
9.1.4.2 Product Benchmarking
9.1.4.3 Strategic Initiatives
9.1.5. PROTEINTECH GROUP, INC.
9.1.5.1 Overview
9.1.5.2 Product Benchmarking
9.1.5.3 Strategic Initiatives
9.1.6. BIO-RAD LABORATORIES INC.
9.1.6.1 Overview
9.1.6.2 Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.6.3 Product Benchmarking
9.1.6.4 Strategic Initiatives
9.1.7. BPS BIOSCIENCE, INC.
9.1.7.1 Overview
9.1.7.2 Product Benchmarking
9.1.7.3 Strategic Initiatives
9.1.8. R&D SYSTEMS, INC.
9.1.8.1 Overview
9.1.8.2 Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.8.3 Product Benchmarking
9.1.8.4 Strategic Initiatives
9.1.9. AGILENT TECHNOLOGIES, INC.
9.1.9.1 Overview
9.1.9.2 Product Benchmarking
9.1.9.3 Strategic Initiatives
9.1.10. ATLAS ANTIBODIES
9.1.10.1 Overview
9.1.10.2 Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.10.3 Product Benchmarking
9.1.10.4 Strategic Initiatives
9.1.11. CUSABIO TECHNOLOGY LLC
9.1.11.1 Overview
9.1.11.2 Product Benchmarking
9.1.11.3 Strategic Initiatives
9.1.12. ROCKLAND IMMUNOCHEMICALS, INC.
9.1.12.1 Overview
9.1.12.2 Product Benchmarking
9.1.12.3 Strategic Initiatives
9.2 Participant’s Overview
9.3 Financial Performance
9.4 Product Benchmarking
9.5 Company Market Share Analysis, 2022
9.6 Strategy Mapping
9.6.1 Expansion
9.6.2 Acquisition
9.6.3 Product/Service Launch
Chapter 10 Analyst View
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global polyclonal antibodies market, by region, 2018 - 2030 (USD Million)
Table 4 Global polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 5 Global polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 6 Global polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 7 Global polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 8 North America polyclonal antibodies market, by country, 2018 - 2030 (USD Million)
Table 9 North America polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 10 North America polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 11 North America polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 12 North America polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 13 U.S. polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 14 U.S. polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 15 U.S. polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 16 U.S. polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 17 Canada polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 18 Canada polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 19 Canada polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 20 Canada polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 21 Europe polyclonal antibodies market, by country, 2018 - 2030 (USD Million)
Table 22 Europe polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 23 Europe polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 24 Europe polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 25 Europe polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 26 Germany polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 27 Germany polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 28 Germany polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 29 Germany polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 30 UK polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 31 UK polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 32 UK polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 33 UK polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 34 France polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 35 France polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 36 France polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 37 France polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 38 Italy polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 39 Italy polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 40 Italy polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 41 Italy polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 42 Spain polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 43 Spain polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 44 Spain polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 45 Spain polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 46 Denmark polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 47 Denmark polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 48 Denmark polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 49 Denmark polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 50 Sweden polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 51 Sweden polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 52 Sweden polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 53 Sweden polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 54 Norway polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 55 Norway polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 56 Norway polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 57 Norway polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 58 Asia Pacific polyclonal antibodies market, by country, 2018 - 2030 (USD Million)
Table 59 Asia Pacific polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 60 Asia Pacific polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 61 Asia Pacific polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 62 Asia Pacific polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 63 Japan polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 64 Japan polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 65 Japan polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 66 Japan polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 67 China polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 68 China polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 69 China polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 70 China polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 71 India polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 72 India polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 73 India polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 74 India polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 75 Australia polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 76 Australia polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 77 Australia polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 78 Australia polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 79 South Korea polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 80 South Korea polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 81 South Korea polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 82 South Korea polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 83 Thailand polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 84 Thailand polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 85 Thailand polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 86 Thailand polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 87 LATAM polyclonal antibodies market, by country, 2018 - 2030 (USD Million)
Table 88 LATAM polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 89 LATAM polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 90 LATAM polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 91 LATAM polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 92 Brazil polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 93 Brazil polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 94 Brazil polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 95 Brazil polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 96 Mexico polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 97 Mexico polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 98 Mexico polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 99 Mexico polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 100 Argentina polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 101 Argentina polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 102 Argentina polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 103 Argentina polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 104 MEA polyclonal antibodies market, by country, 2018 - 2030 (USD Million)
Table 105 MEA polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 106 MEA polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 107 MEA polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 108 MEA polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 109 South Africa polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 110 South Africa polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 111 South Africa polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 112 South Africa polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 113 Saudi Arabia polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 114 Saudi Arabia polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 115 Saudi Arabia polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 116 Saudi Arabia polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 117 UAE polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 118 UAE polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 119 UAE polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 120 UAE polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 121 Kuwait polyclonal antibodies market, by product, 2018 - 2030 (USD Million)
Table 122 Kuwait polyclonal antibodies market, by application, 2018 - 2030 (USD Million)
Table 123 Kuwait polyclonal antibodies market, by source, 2018 - 2030 (USD Million)
Table 124 Kuwait polyclonal antibodies market, by end-user, 2018 - 2030 (USD Million)
Table 125 Company Overview
Table 126 Financial Performance
Table 127 Product Benchmarking
Table 128 Strategic Initiatives
List of Figures
Fig. 1 Polyclonal antibodies market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market outlook (2022)
Fig. 10 Segment Outlook
Fig. 11 Strategy framework
Fig. 12 Market driver relevance analysis (Current & future impact)
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Porter’s five forces analysis
Fig. 15 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 16 Polyclonal antibodies market: Product movement analysis
Fig. 17 Polyclonal antibodies market product outlook: Key takeaways
Fig. 18 Primary antibodies market, 2018 - 2030 (USD Million)
Fig. 19 Secondary antibodies market, 2018 - 2030 (USD Million)
Fig. 20 Polyclonal antibodies market: Application movement analysis
Fig. 21 Polyclonal antibodies market application outlook: Key takeaways
Fig. 22 Biomedical research market, 2018 - 2030 (USD Million)
Fig. 23 Diagnostics market, 2018 - 2030 (USD Million)
Fig. 24 Polyclonal antibodies market: Source movement analysis
Fig. 25 Polyclonal antibodies market source outlook: Key takeaways
Fig. 26 Rabbits market, 2018 - 2030 (USD Million)
Fig. 27 Goats market, 2018 - 2030 (USD Million)
Fig. 28 Sheep market, 2018 - 2030 (USD Million)
Fig. 29 Mouse market, 2018 - 2030 (USD Million)
Fig. 30 Others market, 2018 - 2030 (USD Million)
Fig. 31 Polyclonal antibodies market: End-user movement analysis
Fig. 32 Polyclonal antibodies market end-user outlook: Key takeaways
Fig. 33 Pharmaceutical & biotechnology companies market, 2018 - 2030 (USD Million)
Fig. 34 Hospitals & diagnostic centers market, 2018 - 2030 (USD Million)
Fig. 35 Academic & research center market, 2018 - 2030 (USD Million)
Fig. 36 Regional Outlook, 2023 & 2030
Fig. 37 Regional market place: Key takeaways
Fig. 38 North America polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 39 U.S. polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 40 Canada polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 41 Europe polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 42 UK polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 43 Germany polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 44 France polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 45 Italy polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 46 Spain polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 47 Denmark polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 48 Sweden polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 49 Norway polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 50 Asia Pacific polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 51 Japan polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 52 China polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 53 India polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 54 Australia polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 55 South Korea polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 56 Thailand polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 57 Latin America polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 58 Brazil polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 59 Mexico polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 60 Argentina polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 61 Middle East & Africa polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 62 South Africa polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 63 Saudi Arabia polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 64 UAE polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 65 Kuwait polyclonal antibodies market, 2018 - 2030 (USD Million)
Fig. 66 List of secondary sources

Companies Mentioned

  • THERMO FISHER SCIENTIFIC INC.
  • MERCK KGAA
  • ABCAM PLC.
  • PROTEOGENIX
  • PROTEINTECH GROUP, INC.
  • BIO-RAD LABORATORIES INC.
  • BPS BIOSCIENCE, INC.
  • R&D SYSTEMS, INC.
  • AGILENT TECHNOLOGIES, INC.
  • ATLAS ANTIBODIES
  • CUSABIO TECHNOLOGY LLC
  • ROCKLAND IMMUNOCHEMICALS, INC.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages110
PublishedMay 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 1.48 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.21 Billion
Compound Annual Growth Rate5.0%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

Global Mammalian Polyclonal IgG Antibody Market by Source (Goat, Horse, Mouse), Product (Cardiac Makers, Metabolic Markers, Renal Markers), Application, End-User - Forecast 2024-2030 - Product Image

Global Mammalian Polyclonal IgG Antibody Market by Source (Goat, Horse, Mouse), Product (Cardiac Makers, Metabolic Markers, Renal Markers), Application, End-User - Forecast 2024-2030

  • Report
  • 183 Pages
  • Global
From
Polyclonal Antibodies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Polyclonal Antibodies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 172 Pages
  • Global
From
Polyclonal Antibodies Global Market Report 2024 - Product Image

Polyclonal Antibodies Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
IGY Polyclonal Antibody Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

IGY Polyclonal Antibody Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 112 Pages
  • Global
From
Mammalian Polyclonal IgG Antibody Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 - Product Image

Mammalian Polyclonal IgG Antibody Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

  • Report
  • 145 Pages
  • Global
From

About the Polyclonal Antibodies Market

Polyclonal antibodies are a type of immune disorder drug used to treat a variety of conditions, including autoimmune diseases, allergies, and cancer. These drugs are made up of a mixture of antibodies that are produced by the body in response to a foreign substance, such as a virus or bacteria. They work by targeting and neutralizing the foreign substance, thus preventing it from causing further damage. Polyclonal antibodies can be administered intravenously, intramuscularly, or subcutaneously. Polyclonal antibodies are used to treat a variety of conditions, including rheumatoid arthritis, multiple sclerosis, Crohn's disease, and psoriasis. They are also used to treat certain types of cancer, such as lymphoma and leukemia. In addition, polyclonal antibodies are used to treat allergies, such as hay fever and asthma. The polyclonal antibodies market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.